

Valderilio Feijã³ Azevedo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3518850/publications.pdf>

Version: 2024-02-01

87
papers

1,879
citations

361413

20
h-index

289244

40
g-index

100
all docs

100
docs citations

100
times ranked

2320
citing authors

#	ARTICLE	IF	CITATIONS
1	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 1525-1536.	27.0	405
2	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
3	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
4	Benzbromarone in the treatment of gout. <i>Advances in Rheumatology</i> , 2019, 59, 37.	1.7	70
5	Gender characterization in a large series of Brazilian patients with spondyloarthritis. <i>Clinical Rheumatology</i> , 2012, 31, 687-695.	2.2	59
6	Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies. <i>Joint Bone Spine</i> , 2014, 81, 471-477.	1.6	52
7	TNF-Î±-induced protein 3 (TNFAIP3) /A20 acts as a master switch in TNF-Î± blockade-driven IL-17A expression. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 517-529.	2.9	52
8	High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. <i>RMD Open</i> , 2021, 7, e001461.	3.8	49
9	Etanercept biosimilars. <i>Rheumatology International</i> , 2015, 35, 197-209.	3.0	47
10	Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-5.	1.6	45
11	Rituximab-induced regression of CREST-related calcinosis. <i>Clinical Rheumatology</i> , 2013, 32, 281-283.	2.2	36
12	Effect of Enthesitis on 1505 Brazilian Patients with Spondyloarthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1719-1725.	2.0	35
13	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. <i>Drug Safety</i> , 2020, 43, 379-392.	3.2	28
14	Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. <i>Rheumatology International</i> , 2010, 30, 1411-1416.	3.0	27
15	Potential Regulatory and Commercial Environment for Biosimilars in Latin America. <i>Value in Health Regional Issues</i> , 2012, 1, 228-234.	1.2	27
16	Recommendations for the regulation of biosimilars and their implementation in Latin America. <i>GaBI Journal</i> , 2014, 3, 143-148.	0.3	25
17	Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. <i>Clinical Rheumatology</i> , 2015, 34, 635-640.	2.2	24
18	Consenso Brasileiro de Espondiloartropatias: espondilite anquilosante e artrite psoriásica diagnóstico e tratamento - primeira revisão. <i>Revista Brasileira De Reumatologia</i> , 2007, 47, 233-242.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021, 81, 1859-1879.	10.9	23
20	Ethnic Influence in Clinical and Functional Measures of Brazilian Patients with Spondyloarthritis. <i>Journal of Rheumatology</i> , 2012, 39, 141-147.	2.0	22
21	IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. <i>Rheumatology International</i> , 2013, 33, 1779-1783.	3.0	22
22	Recomendações sobre diagnóstico e tratamento da espondilite anquilosante. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 242-257.	0.8	22
23	Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 769-773.	5.8	21
24	Stiff skin syndrome versus scleroderma: a report of two cases. <i>Clinical Rheumatology</i> , 2009, 28, 1107-1111.	2.2	20
25	Leucopenia e trombocitopenia induzidas por etanercepte: relato de dois casos e revisão da literatura. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 110-112.	0.8	19
26	Occurrence of fibromyalgia in patients with ankylosing spondylitis. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 646-50.	0.8	19
27	Recomendações sobre diagnóstico e tratamento da artrite psoriásica. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 227-241.	0.8	18
28	The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019. <i>Advances in Rheumatology</i> , 2020, 60, 19.	1.7	16
29	Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. <i>Biologics: Targets and Therapy</i> , 2014, 8, 211.	3.2	15
30	Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language. <i>Advances in Rheumatology</i> , 2019, 59, 43.	1.7	14
31	Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. <i>Clinical Rheumatology</i> , 2020, 39, 1859-1869.	2.2	14
32	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
33	Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis. <i>Modern Rheumatology</i> , 2014, 24, 980-984.	1.8	11
34	Biosimilars in rheumatology: perspective and concerns. <i>Rheumatology</i> , 2014, 53, 389-390.	1.9	11
35	Practical Guidance on Biosimilars, With a Focus on Latin America. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 91-100.	0.9	11
36	Home storage of biological medications administered to patients with rheumatic diseases. <i>Advances in Rheumatology</i> , 2020, 60, 30.	1.7	11

#	ARTICLE	IF	CITATIONS
37	Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report. <i>Clinical Rheumatology</i> , 2013, 32, 21-23.	2.2	10
38	Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept. <i>Case Reports in Rheumatology</i> , 2014, 2014, 1-3.	0.6	9
39	Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 24.	2.4	9
40	The biosimilars journey: current status and ongoing challenges. <i>Drugs in Context</i> , 2018, 7, 1-13.	2.2	9
41	Estamos preparados para prescrever biossimilares?. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 221-224.	0.8	9
42	Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab. <i>Rheumatology International</i> , 2009, 29, 1381-1384.	3.0	8
43	Recommendations for the management and treatment of ankylosing spondylitis. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 242-257.	0.7	8
44	Vaccination Recommendations for Adults With Autoimmune Inflammatory Rheumatic Diseases in Latin America. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 138-147.	0.9	8
45	OpiniÃ£o de uma amostra de reumatologistas brasileiros sobre biossimilares. <i>Revista Brasileira De Reumatologia</i> , 2011, 51, 667-671.	0.8	8
46	Biossimilares necessitam de dados clÃnicos comparativos cientificamente confiÃveis. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 129-131.	0.8	7
47	Risk factors and predictors of psoriatic arthritis in patients with psoriasis. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 233-236.	1.1	7
48	Qualidade de vida nas espondiloartrites: anÃlise de uma grande coorte brasileira. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 22-27.	0.8	7
49	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	1.6	7
50	Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. <i>Advances in Rheumatology</i> , 2021, 61, 69.	1.7	7
51	Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. <i>Revista Brasileira De Reumatologia</i> , 2012, 52, 110-2.	0.8	7
52	Concurrent rheumatoid arthritis and ankylosing spondylitis in one patient: the importance of new classification criteria. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 111-119.	0.7	6
53	Recommendations for the management and treatment of psoriatic arthritis. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 227-241.	0.7	6
54	The musculoskeletal impairment negatively impacts the quality of life of children and adolescents with psoriasis. <i>Advances in Rheumatology</i> , 2020, 60, 33.	1.7	6

#	ARTICLE	IF	CITATIONS
55	The Experience with Biosimilars of Infliximab in Rheumatic Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6752-6758.	1.9	6
56	Asymmetric scleroderma in a CVA patient. <i>Clinical Rheumatology</i> , 2008, 27, 1321-1323.	2.2	5
57	Avaliação da aterosclerose subclânica e de níveis plasmáticos de LDL minimamente modificada em pacientes com espondilite anquilosante e sua correlação com a atividade da doença. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 470-475.	0.8	5
58	Custos diretos e indiretos do tratamento de pacientes com espondilite anquilosante pelo sistema público de saúde brasileiro. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 131-137.	0.8	5
59	Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRW4175.	0.7	5
60	New monoclonal antibody biosimilars approved in 2015 in Latin America: position statement of the Latin American Forum on Biosimilars on biosimilarity, interchangeability and extrapolation of indications. <i>GaBI Journal</i> , 2016, 5, 66-69.	0.3	5
61	Doença de Still do Adulto associada à neoplasia de ovário "relato de caso. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 532-534.	0.8	4
62	Critical revision of the medical treatment of gout in Brazil. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 346-355.	0.7	4
63	ProCura - a arte da vida: um projeto pela humanização na saúde. <i>Revista Brasileira De Educacao Medica</i> , 2014, 38, 486-492.	0.2	4
64	Are we prepared to prescribe biosimilars?. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 221-4.	0.8	4
65	Biosimilars require scientifically reliable comparative clinical data. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 127-131.	0.7	3
66	Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritis. <i>Revista Brasileira De Reumatologia</i> , 2014, 54, 33-37.	0.7	3
67	Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis. <i>Advances in Rheumatology</i> , 2021, 61, 4.	1.7	3
68	The Arthritis of Antoni Gaudí. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 367-369.	0.9	2
69	Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab. <i>Reumatismo</i> , 2011, 63, 171-4.	0.9	2
70	Evaluation of sub-clinical atherosclerosis and plasma levels of minimally modified LDL in patients with ankylosing spondylitis and its correlation with disease activity. <i>Revista Brasileira De Reumatologia</i> , 2013, 53, 470-475.	0.7	2
71	Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 131-137.	0.7	2
72	Pelvic Finger. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 403-404.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Risk Factors and Predictors of Psoriatic Arthritis in Patients with Psoriasis. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	1
74	Payer and physician evidence and discount requirements for biosimilars in three Latin American countries. GaBI Journal, 2015, 4, 11-16.	0.3	1
75	Working with folk arts may produce benefits to rheumatic patients: the case of Grandma Moses. Rheumatology, 2008, 47, 1250-1250.	1.9	0
76	Adult Still's disease associated with ovarian cancer - case report. Revista Brasileira De Reumatologia, 2013, 53, 532-534.	0.7	0
77	ASCITE CRÔNICA COMO MANIFESTAÇÃO INICIAL DO LÚPUS ERITEMATOSO SISTÊMICO (LES). Revista Médica Da UFPR, 2014, 1, 63.	0.0	0
78	Clinical profile of pregnant women with systemic lupus erythematosus of the Hospital de Clínicas of the UFPR. Medicina, 2017, 50, 169-176.	0.1	0
79	AB0440...CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. , 2019, , .		0
80	AB0768...BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS. , 2019, , .		0
81	FR10462...UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION. , 2019, , .		0
82	AB0449...PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES. , 2019, , .		0
83	AB0454...FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. , 2019, , .		0
84	Report on the Second PANLAR Review Course in Rheumatology. Journal of Clinical Rheumatology, 2020, 26, 33-36.	0.9	0
85	Clear naming, traceability of biological medicines will protect patients. GaBI Journal, 2017, 6, 153-154.	0.3	0
86	THU0546...Children with psoriasis also show enthesopathy signs related to skin disease activity. , 2018, , .		0
87	Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective. , 0, , .		0